Recro Pharma Net Income

As of the most recent data (December 2023), REPH shows a net income of $-13M. That compares with $-30M in the prior-year period — up 56.1% year over year. That is below the Healthcare sector average of $16B. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, REPH's net income is now $-13M (was $-30M) — a 56.1% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Recro Pharma is outperforming or lagging.

The Healthcare sector average net income is about $16B. Recro Pharma is at $-13M, which is lower that average. That is roughly 100.1% below the sector mean. Use the comparison chart on this page to see how REPH stacks up against individual peers as well.

Tracking REPH's net income over time shows whether Recro Pharma is scaling, shrinking, or reshaping that part of the business. The current reading is $-13M That compares with $-30M in the prior-year period — up 56.1% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this net income page, Stockcircle has Recro Pharma's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect net income (currently $-13M) with ownership activity and broader fundamentals.